Skip to main content
Top
Published in: Current Hypertension Reports 6/2012

01-12-2012 | Pediatric Hypertension (JT Flynn, Section Editor)

What Is the Optimal First-Line Agent in Children Requiring Antihypertensive Medication?

Author: Donald L. Batisky

Published in: Current Hypertension Reports | Issue 6/2012

Login to get access

Abstract

There has been an evolution in the understanding of the treatment of hypertension in children and adolescents over the past decade. This has been fueled in part by the increased attention paid to the clinical problem, given the increasing numbers of children and adolescents being diagnosed with this condition. There has also been a growing number of clinical trials performed and completed that demonstrate the blood pressure (BP)-lowering effects of antihypertensives and the side effect profiles of these medications, and that has led to FDA-labeling of many antihypertensive medications for use in children and adolescents. However, none of these trials has provided definitive data on the optimal first line agent for this patient population. Clinical experience and other approaches discussed in this review are still necessary to guide treatment of hypertension in the young. The quest for the optimal antihypertensive agent is just beginning, and it is going to take some extraordinary effort to reach that goal.
Literature
1.
go back to reference National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–76.CrossRef National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–76.CrossRef
2.
go back to reference Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27:1719–42.PubMedCrossRef Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27:1719–42.PubMedCrossRef
3.
go back to reference •• The Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report, Pediatrics 2011, 128 (Supplement 5): S213–S256. Updated, comprehensive cardiovascular risk reduction guidelines; hypertension section similar to the Fourth Report. •• The Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report, Pediatrics 2011, 128 (Supplement 5): S213–S256. Updated, comprehensive cardiovascular risk reduction guidelines; hypertension section similar to the Fourth Report.
4.
go back to reference Feber J, Ahmed M. Hypertension in children: new trends and challenges. Clin Sci. 2010;119:151–61.PubMedCrossRef Feber J, Ahmed M. Hypertension in children: new trends and challenges. Clin Sci. 2010;119:151–61.PubMedCrossRef
5.
go back to reference Woroniecki RP, Flynn JT. How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol. 2005;20:791–7.PubMedCrossRef Woroniecki RP, Flynn JT. How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol. 2005;20:791–7.PubMedCrossRef
6.
go back to reference Podoll A, Grenier M, Croix B, Feig DI. Inaccuracy in pediatric outpatient blood pressure measurement. Pediatrics. 2007;119:e538–43.PubMedCrossRef Podoll A, Grenier M, Croix B, Feig DI. Inaccuracy in pediatric outpatient blood pressure measurement. Pediatrics. 2007;119:e538–43.PubMedCrossRef
7.
go back to reference Stewart JN, McGillivray D, Sussman J, Foster B. The value of routine blood pressure measurement in children presenting to the emergency department with nonurgent problems. J Pediatr. 2008;153:478–83.PubMedCrossRef Stewart JN, McGillivray D, Sussman J, Foster B. The value of routine blood pressure measurement in children presenting to the emergency department with nonurgent problems. J Pediatr. 2008;153:478–83.PubMedCrossRef
8.
go back to reference Lande MB, Flynn JT. Treatment of hypertension in children and adolescents. Pediatr Nephrol. 2009;24:1939–49.PubMedCrossRef Lande MB, Flynn JT. Treatment of hypertension in children and adolescents. Pediatr Nephrol. 2009;24:1939–49.PubMedCrossRef
9.
go back to reference Batisky DL. Obesity and the role of lifestyle and dietary intervention in the management of pediatric hypertension. J Med Liban. 2010;58:171–4.PubMed Batisky DL. Obesity and the role of lifestyle and dietary intervention in the management of pediatric hypertension. J Med Liban. 2010;58:171–4.PubMed
10.
go back to reference Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol. 2009;24:1101–12.PubMedCrossRef Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol. 2009;24:1101–12.PubMedCrossRef
11.
go back to reference Flynn JT. Pediatric hypertension: recent trends and accomplishments, future challenges. Am J Hypertens. 2008;21:605–12.PubMedCrossRef Flynn JT. Pediatric hypertension: recent trends and accomplishments, future challenges. Am J Hypertens. 2008;21:605–12.PubMedCrossRef
12.
go back to reference Flynn JT, Falkner BE. Obesity hypertension in adolescents: epidemiology, evaluation, and management. J Clin Hypertens. 2011;13:323–31.CrossRef Flynn JT, Falkner BE. Obesity hypertension in adolescents: epidemiology, evaluation, and management. J Clin Hypertens. 2011;13:323–31.CrossRef
13.
go back to reference Batisky DL. Blood pressure variability, prehypertension, and hypertension in adolescents. Adolesc Health, Med Ther. 2012;3:1–8. Batisky DL. Blood pressure variability, prehypertension, and hypertension in adolescents. Adolesc Health, Med Ther. 2012;3:1–8.
14.
go back to reference Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. JAMA. 2003;289:2560–72.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. JAMA. 2003;289:2560–72.PubMedCrossRef
15.
go back to reference •• Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A, Pezous N, Kadwa M. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens. 2011;29:2484–90. Only recent clinical trial in pediatric hypertension comparing two different classes of agents. PubMedCrossRef •• Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A, Pezous N, Kadwa M. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens. 2011;29:2484–90. Only recent clinical trial in pediatric hypertension comparing two different classes of agents. PubMedCrossRef
16.
go back to reference Brierley J, Marks SD. Treating the causes of paediatric hypertension using non-invasive physiologic parameters. Med Hypoth. 2010;75:439–41.CrossRef Brierley J, Marks SD. Treating the causes of paediatric hypertension using non-invasive physiologic parameters. Med Hypoth. 2010;75:439–41.CrossRef
17.
go back to reference Laragh JH. Abstract, closing summary, and table of contents for Laragh’s 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension. Am J Hypertens. 2001;14:1173–7.PubMedCrossRef Laragh JH. Abstract, closing summary, and table of contents for Laragh’s 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension. Am J Hypertens. 2001;14:1173–7.PubMedCrossRef
18.
go back to reference Laragh JH, Sealey JE. The Plasma Renin Test Reveals the Contribution of Body Sodium-Volume Content (V) and Renin-Angiotensin (R) Vasoconstriction to Long-Term Blood Pressure. Am J Hypertens. 2011;24:1164–80.PubMedCrossRef Laragh JH, Sealey JE. The Plasma Renin Test Reveals the Contribution of Body Sodium-Volume Content (V) and Renin-Angiotensin (R) Vasoconstriction to Long-Term Blood Pressure. Am J Hypertens. 2011;24:1164–80.PubMedCrossRef
19.
go back to reference Flynn JT. Management of hypertension in the young: role of antihypertensive medications. J Cardiovasc Pharmacol. 2011;58:111–20.PubMedCrossRef Flynn JT. Management of hypertension in the young: role of antihypertensive medications. J Cardiovasc Pharmacol. 2011;58:111–20.PubMedCrossRef
20.
go back to reference Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich). 2003;5:330–55.CrossRef Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich). 2003;5:330–55.CrossRef
21.
go back to reference Flynn JT, Newburger JW, Daniels SW, et al. for the PATH-1 Investigators. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145:353–9.PubMedCrossRef Flynn JT, Newburger JW, Daniels SW, et al. for the PATH-1 Investigators. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145:353–9.PubMedCrossRef
22.
go back to reference •• Blowey DL. Update on the pharmacologic treatment of hypertension in pediatrics. J Clin Hypertens. 2012;14:383–7. This reference is a concise, well-organized, and current review of this topic. CrossRef •• Blowey DL. Update on the pharmacologic treatment of hypertension in pediatrics. J Clin Hypertens. 2012;14:383–7. This reference is a concise, well-organized, and current review of this topic. CrossRef
23.
go back to reference Seeman T, Gilik J, Vondrak K, et al. Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J Hypertens. 2007;20:990–6.PubMedCrossRef Seeman T, Gilik J, Vondrak K, et al. Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J Hypertens. 2007;20:990–6.PubMedCrossRef
24.
go back to reference Wühl E, Mehls O, Schaefer F, ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66:768–76.PubMedCrossRef Wühl E, Mehls O, Schaefer F, ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66:768–76.PubMedCrossRef
25.
go back to reference •• Welch WP, Yang W, Taylor-Zapata P, Flynn JT. Anti-hypertensive drug use by children: are the drugs labeled and indicated? J Clin Hypertens. 2012;14:388–95. Demonstrates ongoing use of antihypertensive medications despite lack of FDA-approved pediatric labeling. CrossRef •• Welch WP, Yang W, Taylor-Zapata P, Flynn JT. Anti-hypertensive drug use by children: are the drugs labeled and indicated? J Clin Hypertens. 2012;14:388–95. Demonstrates ongoing use of antihypertensive medications despite lack of FDA-approved pediatric labeling. CrossRef
Metadata
Title
What Is the Optimal First-Line Agent in Children Requiring Antihypertensive Medication?
Author
Donald L. Batisky
Publication date
01-12-2012
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 6/2012
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-012-0302-7

Other articles of this Issue 6/2012

Current Hypertension Reports 6/2012 Go to the issue

Special Situations in the Management of Hypertension (T Kotchen, Section Editor)

Novel Antihypertensive Therapies: Renal Sympathetic Nerve Ablation and Carotid Baroreceptor Stimulation

Pediatric Hypertension (JT Flynn, Section Editor)

Progression of Prehypertension to Hypertension in Adolescents

Mediators, Mechanisms, and Pathways in Tissue Injury (B Rothermel, Section Editor)

Mechanisms of Lipotoxicity in the Cardiovascular System

Pediatric Hypertension (JT Flynn, Section Editor)

Ambulatory Blood Pressure Monitoring in Pediatric Renal Transplantation

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.